Sanofi to acquire Ablynx

Unanimously approved by Sanofi and Ablynx Boards of Directors

29-Jan-2018 - Sanofi and Ablynx entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 in cash, which ...

ABLYNX appoints Markus Ewert as Chief Business Officer

14-Jun-2017 - Ablynx announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead the Company's business development and corporate strategy activities and become a member of the Executive Committee. Dr Ewert has worked for nearly 30 ...

Ablynx to receive milestone for bi-specific nanobody in oncology

01-Feb-2016 - Ablynx announced that Boehringer Ingelheim has administered the first dose in a Phase I dose escalation study with the half-life extended bi-specific anti-VEGF/Ang2 Nanobody® in adult patients with advanced solid tumors, triggering an €8 million milestone payment to Ablynx. The aim of the study ...

Genzyme to collaborate with Ablynx on MS research project

19-May-2015 - Ablynx announced that it has entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate Nanobodies® against a target that plays an important role in multiple sclerosis (MS) and specifically aligns with Genzyme's early-stage MS research programs involving ...

Ablynx extends ion channel research collaboration with Merck & Co.

27-Mar-2015 - Ablynx announced an extension of its initial two-year research collaboration with Merck & Co., Inc., known as MSD outside the United States and Canada, to develop and commercialise Nanobody® candidates directed towards an undisclosed voltage gated ion channel.Merck & Co., Inc. will extend their ...

Ablynx successfully raises €41.7 million

03-Jul-2014 - Ablynx announces that it has raised €41,720,822 through a private placement of new shares via an accelerated book building procedure announced on 30 June 2014. The private placement has allowed Ablynx to place 4,908,332 new shares with domestic and international institutional investors at a ...

Ablynx's anti-vWF Nanobody achieves clinical proof-of-concept in Phase II TITAN study

First-in-class potential with orphan drug status for the treatment of acquired thrombotic thrombocytopenic purpura

18-Jun-2014 - Ablynx announced that it has achieved positive results in the Phase II TITAN study with the anti-vWF Nanobody®, caplacizumab, in patients with acquired thrombotic thrombocytopenic purpura (TTP), a rare disorder of the blood coagulation system that causes microthrombi to form which can block small ...

Ablynx announces cancer immunotherapy discovery collaboration with Merck

04-Feb-2014 - Ablynx announced that the company has entered into a second research collaboration and licensing agreement with a subsidiary of Merck & Co., known outside the US and Canada as MSD. This new exclusive collaboration and licensing agreement is focused on the discovery and development of several ...

Co-discovery and co-development of nanobodies

27-Sep-2013 - Merck Serono and Ablynx announced that they have further expanded their relationship through a multi-year research alliance that could lead to several co-discovery and co-development collaborations. Under the terms of the agreement, Merck Serono will fund a dedicated discovery group at Ablynx. ...

Ablynx and Spirogen enter in research collaboration for toxin-nanobody drug conjugates

26-Feb-2013 - Ablynx and Spirogen Ltd. announced a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary ...